Alarmin molecule identified as therapeutic target for allergic respiratory diseases

One of the molecules responsible for triggering the inflammation that causes allergic respiratory diseases, such as asthma and allergic rhinitis, has just been discovered by scientists from the CNRS, Inserm and the Université Toulouse III – Paul Sabatier.

Almirall to license Eloxx’s ZKN-013 for rare skin conditions

Share this article Almirall will develop and market the drug candidate for rare dermatological ailments. Credit: JPC-PROD / Shutterstock.com. Almirall has signed an exclusive licence

March 14, 2024

FDA adcomm supports first potential drug for ultra-rare, fatal Barth syndrome

Heart-breaking anecdotes from the patients, parents and doctors of children with the ultra-rare and fatal Barth syndrome won over an FDA advisory committee on Thursday

October 11, 2024

Assessing recurrence risk with ctDNA-based MRD detection in NSCLC patients

In operable non-small cell lung cancer (NSCLC), molecular residual disease (MRD) detection via circulating tumor DNA (ctDNA) has emerged as a promising approach to identify

November 7, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.